Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 First Extraordinary General Meeting

Time:2024-01-18

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Approval Notice for Clinical Trial

Time:2024-01-11

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Compound Ipratropium Bromide Solution for Inhalation Obtaining Drug Registration Approval in Philippine

Time:2024-01-09

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Provision for Impairment of Assets

Time:2024-01-09

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 First Extraordinary General Meeting

Time:2023-12-28

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Inclusion of the Company‘s Products in the National Reimbursement Drug List

Time:2023-12-13

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Progress of the Application for the Listing of Livzon Diagnostics, a Majority-owned Subsidiary of Livzon Group, on the NEEQ

Time:2023-12-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Fourth Extraordinary General Meeting

Time:2023-12-08

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement On Clinical Trial Approval of Meloxicam Nanocrystal Injection

Time:2023-12-04

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement On the Inclusion of Recombinant Sars-Cov-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) For Emergency Use

Time:2023-12-03

< 1...91011...16 >